Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | ERBB2 T862A |
Gene Variant Detail | |
Relevant Treatment Approaches | HER inhibitor (Pan) HER2 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
ERBB2 T862A | Advanced Solid Tumor | resistant | HER2 Inhibitor | Sapitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) T862A demonstrated resistance to Sapitinib (AZD8931) treatment in culture (PMID: 29967253). | 29967253 |
ERBB2 T862A | Advanced Solid Tumor | predicted - sensitive | HER2 Inhibitor | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) T862A demonstrated partial sensitivity to Tykerb (lapatinib) treatment in culture (PMID: 29967253). | 29967253 |
ERBB2 T862A | Advanced Solid Tumor | predicted - sensitive | HER2 Inhibitor | Lapatinib | Preclinical | Actionable | In a preclinical study, higher dose of Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) N862A in culture (PMID: 22046346). | 22046346 |
ERBB2 T862A | Advanced Solid Tumor | sensitive | HER2 Inhibitor | AEE788 | Preclinical | Actionable | In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) T862A in culture (PMID: 22046346). | 22046346 |
ERBB2 T862A | Advanced Solid Tumor | resistant | Trastuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) T862A demonstrated resistance to Herceptin (trastuzumab) treatment in culture (PMID: 29967253). | 29967253 | |
ERBB2 T862A | Advanced Solid Tumor | sensitive | HER2 Inhibitor | Neratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nerlynx (neratinib) treatment inhibited viability of transformed cells expressing ERBB2 (HER2) T862A in culture (PMID: 29967253). | 29967253 |
ERBB2 T862A | Advanced Solid Tumor | sensitive | Osimertinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tagrisso (osimertinib) treatment inhibited viability of transformed cells expressing ERBB2 (HER2) T862A in culture (PMID: 29967253). | 29967253 | |
ERBB2 T862A | Advanced Solid Tumor | sensitive | HER inhibitor (Pan) | Afatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Gilotrif (afatinib) treatment inhibited viability of transformed cells expressing ERBB2 (HER2) T862A in culture (PMID: 29967253). | 29967253 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|